Videos
Metastatic Hormone-Sensitive Prostate Cancer Progression to CRPC
Myung-Ju Ahn, MD, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, discusses the findings from the AURA LM study, which compared an 80 mg dose of osimertinib with a 160 mg dose in patients with <em>EGFR</em>-positive advanced non–small cell lung cancer with leptomeningeal metastases.
William G. Wierda, MD, PhD, discusses the take home message from the phase III MURANO trial that identified venetoclax plus rituximab as a new treatment option for patients with relapsed/refractory chronic lymphocytic leukemia.
Andre Goy, MD, discusses the role of rituximab and bendamustine plus cytarabine as a treatment for patients with mantle cell lymphoma.
Tony Mok, MD, discusses the next steps for pembrolizumab (Keytruda) as a treatment option for patients with non-small cell lung cancer after the phase III KEYNOTE-042 trial.
Alexander E. Perl, MD, discusses the latest advancements in the treatment landscape for patients with acute myeloid leukemia. These advances are driven by 2 factors: a better understanding of the biology of the disease and improving therapeutics to meet that understanding.
Bladder Cancer
Relapse After Second-Line Therapy in Follicular Lymphoma
Ryan J. Sullivan, MD, discusses the role of checkpoint inhibitors in the treatment landscape for patients with melanoma.
Elias Jabbour, MD, discusses the latest advancements in the treatment landscape for acute lymphocytic leukemia that are moving the paradigm away from chemotherapy.
